Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 14, 2025 06:04 ET | Source: Research and Markets

Europe Glucagon-like Peptide-1 (GLP-1) Agonists Research Report 2025 | Market to Reach $14.34 Billion by 2034, Driven by Innovative R&D, Strategic Collaborations, and Drug Formulation Advancements

Dublin, July 14, 2025 (GLOBE NEWSWIRE) -- The "Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Report and Forecast 2025-2034" has been added to ResearchAndMarkets.com's offering. The...
July 14, 2025 05:56 ET | Source: Research and Markets

GLP-1 Agonists Drug Pipeline Analysis Market Report 2025 | Next-generation GLP-1 Agonists Pave the Way for Diabetes and Obesity Management

Dublin, July 14, 2025 (GLOBE NEWSWIRE) -- The "GLP-1 Agonists Drug Pipeline Analysis Report 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.The GLP-1 Agonists Drug Pipeline...
July 10, 2025 10:52 ET | Source: Research and Markets

United States Glucagon-like Peptide-1 (GLP-1) Agonists Market Report 2025-2034 | Expanding Clinical Trials and Increasing Insurance Coverage to Boost Growth Prospects

Dublin, July 10, 2025 (GLOBE NEWSWIRE) -- The "United States Glucagon-like Peptide-1 (GLP-1) Agonists Market Report and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's...
July 02, 2025 05:43 ET | Source: Research and Markets

Semaglutide Market Forecast Report 2025-2033 | Growth Accelerates Amid Rising Awareness, Regulatory Approvals, and Strong Pipeline Advancements

Dublin, July 02, 2025 (GLOBE NEWSWIRE) -- The "Semaglutide Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ResearchAndMarkets.com's...
June 17, 2025 09:04 ET | Source: PMGC Holdings Inc.

Northstrive Biosciences Announces Initiation of Phase II of Collaboration to Develop AI Powered Therapies for Obesity and Cardiometabolic Diseases

NorthStrive Biosciences Announces Initiation of Phase II of Collaboration to Develop AI Powered Therapies for Obesity and Cardiometabolic Diseases
May 27, 2025 12:39 ET | Source: Sagapixel

Sagapixel: GLP-1 Surpasses Ozempic in Search Volume, Signaling a New Era in Patient Awareness and Provider Strategy

Sagapixel reports “GLP-1” has overtaken “Ozempic” in search volume, signaling a major shift in patient awareness and provider marketing and SEO strategy.
May 22, 2025 08:16 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Related Sarcopenia

NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Re
May 22, 2025 04:13 ET | Source: Research and Markets

Semaglutide (Ozempic, Wegovy, Rybelsus) Market Trends Analysis and Growth Report 2025-2035: Emerging Markets and Oral Formulations Present New Frontiers for Expansion

Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Semaglutide Market Size, Share & Trends Analysis Report by Product (Ozempic, Wegovy, Rybelsus), Application (Type 2 Diabetes Mellitus, Obesity),...
May 13, 2025 08:00 ET | Source: PMGC Holdings Inc.

Northstrive Biosciences Signs Binding Term Sheet with Modulant Biosciences for Exclusive Global Animal Health Licensing of EL-22

Northstrive Biosciences Signs Binding Term Sheet with Modulant Biosciences for Exclusive Global Animal Health Licensing of EL-22
April 29, 2025 12:15 ET | Source: PMGC Holdings Inc.

RESEND - Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health

Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health

Next Page keyboard_arrow_right